product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Met (D1C2) XP® Rabbit mAb
catalog :
8198S
quantity :
100 ul
price :
260 USD
clonality :
monoclonal
host :
rabbit
reactivity :
human
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section, other
more info or order :
Cell Signaling Technology product webpage
citations: 15
Published Application/Species/DilutionReference
  • immunohistochemistry - paraffin section; human; 1:100; fig s4
  • other; human; 1:400; fig s3
  • western blot; human; 1:1000; fig s1
  • immunocytochemistry; human; 1:1000; fig s2
De Herdt M, Willems S, van der Steen B, Noorlag R, Verhoef E, van Leenders G, et al. Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma. Oncotarget. 2016;7:13167-81 pubmed publisher
  • western blot; human; fig 9a
Yokdang N, Hatakeyama J, Wald J, Simion C, Tellez J, Chang D, et al. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells. Oncogene. 2016;35:2932-47 pubmed publisher
  • western blot; human; fig 5
Kobayashi K, Sakurai K, Hiramatsu H, Inada K, Shiogama K, Nakamura S, et al. The miR-199a/Brm/EGR1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines. Sci Rep. 2015;5:8428 pubmed publisher
  • immunohistochemistry; human; 1:300; fig 2
Ciamporcero E, Miles K, Adelaiye R, Ramakrishnan S, Shen L, Ku S, et al. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther. 2015;14:101-10 pubmed publisher
  • immunohistochemistry - paraffin section; human
  • western blot; human
Navis A, van Lith S, van Duijnhoven S, de Pooter M, Yetkin-Arik B, Wesseling P, et al. Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathol. 2015;130:131-44 pubmed publisher
  • western blot; human; 1:1000; fig 2
Zucha M, Wu A, Lee W, Wang L, Lin W, Yuan C, et al. Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget. 2015;6:13255-68 pubmed
  • western blot; human; fig 5
Le A, Huang Y, Pingle S, Kesari S, Wang H, Yong R, et al. Plexin-B2 promotes invasive growth of malignant glioma. Oncotarget. 2015;6:7293-304 pubmed
  • western blot; human; fig 3g
Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson A, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 2015;522:349-53 pubmed publisher
  • immunoprecipitation; human
  • western blot; human
Cen B, Xiong Y, Song J, Mahajan S, DuPont R, McEachern K, et al. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 2014;34:2517-32 pubmed publisher
  • immunocytochemistry; human; 1:50
Xie Y, Lu W, Liu S, Yang Q, Carver B, Li E, et al. Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer. Mol Endocrinol. 2014;28:1629-39 pubmed publisher
Yoshida T, Zhang G, Smith M, Lopez A, Bai Y, Li J, et al. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin Cancer Res. 2014;20:4059-74 pubmed publisher
Wu J, Yu J, Wu H, Zheng L, Ni X, Li X, et al. Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma. BMC Res Notes. 2014;7:6 pubmed publisher
Ach T, Zeitler K, Schwarz-Furlan S, Baader K, Agaimy A, Rohrmeier C, et al. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch. 2013;462:65-72 pubmed publisher
Navis A, Bourgonje A, Wesseling P, Wright A, Hendriks W, Verrijp K, et al. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. PLoS ONE. 2013;8:e58262 pubmed publisher
Casbas-Hernandez P, D'arcy M, Roman-Perez E, Brauer H, McNaughton K, Miller S, et al. Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. Breast Cancer Res. 2013;15:R82 pubmed
product information
SKU :
8198S
Product-Name :
Met (D1C2) XP® Rabbit mAb
Size :
100 ul
Price-(USD) :
260 USD
Species-x-Reactivity :
H
Applications :
Flow cytometry
Product-Category :
RTK
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
140, 170
Host :
Rabbit
Target :
Met
Primary-Protein :
Met
Alt-Names :
AUTS9,HGF receptor,HGF/SF receptor,HGFR,Hepatocyte growth factor receptor,MET,Proto-oncogene c-Met,RCCP2,SF receptor,Scatter factor receptor,Tyrosine-protein kinase Met,c-Met,met proto-oncogene (hepatocyte growth factor receptor),met proto-oncogene tyrosine kinase,oncogene MET
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.